International Journal of Clinical Research

Objective: To explore and analyze the safety of different combinations of tenofovir tablets in the treatment of AIDS. Methods: 98 patients with AIDS who received treatment in our hospital from February 2018 to February 2022 were selected as the research objects and randomly divided into the control group and the study group. The control group was treated with efaviren, tenofovir, and lamivudine, while the study group was treated with lamivudine, tenofovir, and clonidazole. After treatment, the incidence of lymphocyte counts, HIV viral load, clinical indicators, renal toxicity, and bone mineral density effects were compared between the two groups. Results: The CD4+count in the study group was higher than that in the control group, and the HIV viral load level was lower than that in the control group, with significant differences (P<0.05). There was no significant difference in the incidence of nephrotoxicity and bone mineral density effects (P>0.05). Conclusion: The combination of lamivudine, tenofovir, and clonidazole can effectively inhibit the replication and diffusion of HIV virus in humans, delay the progression of the disease, but have a significant impact on renal toxicity and bone mineral density.

AIDS; Tenofovir tablets; Lamivudine tablets; Incidence of nephrotoxicity and bone mineral density effects